{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:46Z","timestamp":1782337306795,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["2025SRP003"],"award-info":[{"award-number":["2025SRP003"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["02\\u2013410\\u20132302068XM"],"award-info":[{"award-number":["02\\u2013410\\u20132302068XM"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0209700"],"award-info":[{"award-number":["2022YFE0209700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024A03J0891"],"award-info":[{"award-number":["2024A03J0891"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["SL2022A03J00613"],"award-info":[{"award-number":["SL2022A03J00613"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["202201011593"],"award-info":[{"award-number":["202201011593"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171312"],"award-info":[{"award-number":["32171312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072047"],"award-info":[{"award-number":["82072047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drup.2025.101316","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:04:34Z","timestamp":1760803474000},"page":"101316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells"],"prefix":"10.1016","volume":"84","author":[{"given":"Lingmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-7735","authenticated-orcid":false,"given":"Yinshan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9927-0715","authenticated-orcid":false,"given":"Shiqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-2506","authenticated-orcid":false,"given":"Liwu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-7338","authenticated-orcid":false,"given":"Xi-Yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2025.101316_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1089\/jir.2015.0179","article-title":"Chromatin landscape of the IRF genes and role of the epigenetic reader BRD4","volume":"36","author":"Bachu","year":"2016","journal-title":"J. Interferon Cytok. Res."},{"key":"10.1016\/j.drup.2025.101316_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2025.101316_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41389-021-00316-z","article-title":"Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4","volume":"10","author":"Calder","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drup.2025.101316_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2020.05.028","article-title":"Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy","volume":"112","author":"Chen","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drup.2025.101316_bib5","article-title":"Cell membrane biomimetic nanomedicines for cancer phototherapy","volume":"1","author":"Chen","year":"2023","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.drup.2025.101316_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113731","article-title":"Magnetically controlled nanorobots induced oriented and rapid clearance of the cytokine storm for acute lung injury therapy","volume":"234","author":"Chen","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.drup.2025.101316_bib7","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101316_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107304","article-title":"Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer","volume":"206","author":"Dai","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.drup.2025.101316_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.7150\/thno.92526","article-title":"Degraders in epigenetic therapy: PROTACs and beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2025.101316_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2025.101316_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606209","article-title":"Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization","volume":"29","author":"Dehaini","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2025.101316_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101316_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107198","article-title":"Macrophages and tumor-associated macrophages in the senescent microenvironment: from immunosuppressive TME to targeted tumor therapy","volume":"204","author":"Du","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drup.2025.101316_bib14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C8MD00198G","article-title":"Targeting Brd4 for cancer therapy: inhibitors and degraders","volume":"9","author":"Duan","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.drup.2025.101316_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2025.101316_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206200","article-title":"Engineered bacterial outer membrane vesicles as controllable two-way adaptors to activate macrophage phagocytosis for improved tumor immunotherapy","volume":"34","author":"Feng","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2025.101316_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12951-020-00649-8","article-title":"Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy","volume":"18","author":"Gong","year":"2020","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.drup.2025.101316_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.drup.2025.101316_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature15373","article-title":"Nanoparticle biointerfacing by platelet membrane cloaking","volume":"526","author":"Hu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101316_bib20","article-title":"New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resist. Update. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.drup.2025.101316_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drudis.2021.08.007","article-title":"Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: current situation and future directions","volume":"27","author":"Jin","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2025.101316_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.271","article-title":"Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents","volume":"7","author":"Klingbeil","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101316_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/IJN.S334331","article-title":"Direct detection of pulmonary fibrosis by near-infrared-responsive biomimetic platelets","volume":"17","author":"Li","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drup.2025.101316_bib24","doi-asserted-by":"crossref","first-page":"57732","DOI":"10.1021\/acsami.0c18287","article-title":"High-performance dual combination therapy for cancer treatment with hybrid membrane-camouflaged mesoporous silica gold nanorods","volume":"12","author":"Li","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.drup.2025.101316_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12951-021-01107-9","volume":"19","author":"Li","year":"2021","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.drup.2025.101316_bib26","doi-asserted-by":"crossref","first-page":"26614","DOI":"10.1021\/acsnano.4c04814","article-title":"Platelet and erythrocyte membranes coassembled biomimetic nanoparticles for heart failure treatment","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.drup.2025.101316_bib27","article-title":"Cancer-associated fibroblasts: heterogeneity, cancer pathogenesis, and therapeutic targets","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.drup.2025.101316_bib28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12943-022-01651-4","article-title":"The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy","volume":"21","author":"Liang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101316_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"EbioMedicine"},{"key":"10.1016\/j.drup.2025.101316_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.7150\/thno.104872","article-title":"Metformin-based nanomedicines for reprogramming tumor immune microenvironment","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2025.101316_bib31","article-title":"Cancer cell membrane-based materials for biomedical applications","volume":"20","author":"Lu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.drup.2025.101316_bib32","article-title":"Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma","volume":"24","author":"Ma","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.drup.2025.101316_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An updated patent review of BRD4 degraders","volume":"34","author":"Ma","year":"2024","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.drup.2025.101316_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jcis.2021.06.066","article-title":"Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer","volume":"603","author":"Peng","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.drup.2025.101316_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12951-022-01547-x","article-title":"Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment","volume":"20","author":"Qin","year":"2022","journal-title":"J. Nanobiotechnol"},{"key":"10.1016\/j.drup.2025.101316_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215860","article-title":"Cancer-associated fibroblasts: an emerging target against esophageal squamous cell carcinoma","volume":"546","author":"Qiu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101316_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abj5879","article-title":"IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells","volume":"15","author":"Remsing Rix","year":"2022","journal-title":"Sci. Signal"},{"key":"10.1016\/j.drup.2025.101316_bib38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2025.101316_bib39","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s11095-022-03184-3","article-title":"Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera","volume":"39","author":"Vartak","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drup.2025.101316_bib40","doi-asserted-by":"crossref","first-page":"7323","DOI":"10.1007\/s12274-023-5394-7","article-title":"Targeting cancer-associated fibroblasts with hydroxyethyl starch nanomedicine boosts cancer therapy","volume":"16","author":"Wang","year":"2023","journal-title":"Nano Res"},{"key":"10.1016\/j.drup.2025.101316_bib41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101316_bib42","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2025.101316_bib43","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","article-title":"Stromal induction of BRD4 phosphorylation results in chromatin remodeling and BET inhibitor resistance in colorectal cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101316_bib44","article-title":"Red blood cell derived nanocarrier drug delivery system: a promising strategy for tumor therapy","volume":"2","author":"Wang","year":"2024","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.drup.2025.101316_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2025.101316_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101098","article-title":"Application of biomimetic nanovaccines in cancer immunotherapy: a useful strategy to help combat immunotherapy resistance","volume":"75","author":"Xu","year":"2024","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.drup.2025.101316_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101175","article-title":"Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer","volume":"78","author":"Yang","year":"2025","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2025.101316_bib48","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2025.101316_bib49","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41467-020-15290-0","article-title":"Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction","volume":"11","author":"Yin","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101316_bib50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1078-0432.CCR-14-0846","article-title":"Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation","volume":"21","author":"Yoshida","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2025.101316_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100915","article-title":"Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy","volume":"67","author":"Yu","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2025.101316_bib52","article-title":"Cell membrane-coated nanomaterials for cancer therapy","volume":"20","author":"Zeng","year":"2023","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.drup.2025.101316_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.009","article-title":"Cancer-associated fibroblasts in non-small cell lung cancer: recent advances and future perspectives","volume":"514","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101316_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2025.101316_bib55","article-title":"Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2025.101316_bib56","article-title":"Homotypic targeting delivery of siRNA with artificial cancer cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.drup.2025.101316_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.192","article-title":"Targeting inorganic nanoparticles to tumors using biological membrane-coated technology","volume":"3","author":"Zhang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.drup.2025.101316_bib58","doi-asserted-by":"crossref","first-page":"28034","DOI":"10.1021\/acsami.0c07559","article-title":"Artificial platelets for efficient siRNA delivery to clear \u201cbad cholesterol","volume":"12","author":"Zhang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.drup.2025.101316_bib59","article-title":"Dendritic polymer-based nanomedicines remodel the tumor stroma: improve drug penetration and enhance antitumor immune response","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2025.101316_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230004","article-title":"From classic medicinal chemistry to state-of-the-art interdisciplinary Medicine: recent advances in proteolysis-targeting chimeras technology","volume":"1","author":"Zhao","year":"2023","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.drup.2025.101316_bib61","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2020.02.018","article-title":"MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression","volume":"476","author":"Zheng","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101316_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:23:03Z","timestamp":1773256983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":62,"alternative-id":["S1368764625001190"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101316","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101316"}}